Skip to content
2000
Volume 10, Issue 4
  • ISSN: 1566-5240
  • E-ISSN: 1875-5666

Abstract

Alterations in TGFß signaling are common in human cancers. TGFß has significant impact on tumor initiation and progression. Therapeutic strategies including neutralizing antibodies and small molecular inhibitors have been developed to target TGFß signaling. However, TGFß can work as both a tumor suppressor and a tumor promoter. A significant challenge to the development of successful TGFß antagonism treatment is understanding how and when TGFß switches its function from a tumor suppressor to a tumor promoter. Recent studies demonstrate that TGFß regulates the infiltration of inflammatory cells and cancer associated fibroblasts into the tumor microenvironment, resulting in changes in signaling cascade in tumor cells. Additionally, TGFß exerts systemic immune suppression and significantly inhibits host tumor immune surveillance. Neutralizing TGFß in preclinical mouse models enhances CD8+ T-cell and natural killer cell-mediated anti-tumor immune response. This new understanding of TGFß signaling in regulation of tumor microenvironment and immune response may provide useful information, particularly for patient selection and inflammation/immune biomarkers for TGFß antagonism therapy in clinical trials.

Loading

Article metrics loading...

/content/journals/cmm/10.2174/156652410791317039
2010-06-01
2025-06-12
Loading full text...

Full text loading...

/content/journals/cmm/10.2174/156652410791317039
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test